FOXM1 and hepatocellular carcinoma: In a study, the authors have demonstrated that LXR agonists can downregulate forkhead box M1 (FOXM1) in HCC cells, thereby inhibiting the expression of cyclin D1 and cyclin B1, leading to cell cycle and proliferation arrest.112